Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119867 | 0.89 | MAPT (0.41) | NAMPTPTGDR2MTNR1B | |
| SCHEMBL4127584 | 0.89 | HTR6 (0.35) | NFE2L2NAMPT | |
| SCHEMBL4130442 | 0.88 | KMT2A (0.38) | NAMPT | |
| SCHEMBL4139211 | 0.88 | LIPG (0.36) | SLC40A1NAMPT | |
| SCHEMBL4125431 | 0.87 | DHODH (0.36) | NFE2L2SLC40A1NAMPTPTGDR2 | |
| SCHEMBL3648852 | 0.85 | NFE2L2 (0.39) | NFE2L2GLO1SLC40A1NAMPTPTGDR2 | |
| SCHEMBL4120655 | 0.85 | NFE2L2 (0.39) | NFE2L2GLO1SLC40A1NAMPTNPC1 | |
| SCHEMBL4131245 | 0.84 | ALDH1A1 (0.34) | SLC40A1NAMPTABCC9ABCC8KCNJ11 | |
| SCHEMBL4118456 | 0.84 | LIPG (0.33) | SLC40A1MAPK14PTGDR2 | |
| Hydrochloric Acid SCHEMBL3655968 | 0.84 | NFE2L2 (0.41) | NFE2L2GLO1SLC40A1NAMPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NFE2L2 2670/4885GLO1 3197/4885SLC40A1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.